Clinical Trials Logo

Melanoma Stage clinical trials

View clinical trials related to Melanoma Stage.

Filter by:
  • None
  • Page 1

NCT ID: NCT03449615 Recruiting - Sentinel Lymph Node Clinical Trials

Validation of Ferromagnetic Tracer in Melanoma Sentinel Node

IMINEM
Start date: December 21, 2015
Phase: N/A
Study type: Observational

This study has been designed to validate a non-radioactive method to identify the sentinel lymph node using a superparamagnetic iron-oxide (SPIO) tracer respect to the traditional isotopic method. Both methods are used in every included patient and each patient is its own control.

NCT ID: NCT03224208 Terminated - Melanoma Clinical Trials

Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients

VECODUE
Start date: May 17, 2018
Phase: Phase 2
Study type: Interventional

In the BRIM-3 trial, which was conducted in patients with previously untreated advanced melanoma harboring the BRAF V600E mutation, vemurafenib, a potent inhibitor of mutated BRAF, was associated with prolonged overall survival (OS) and progression-free survival (PFS) compared to dacarbazine. In the same setting, combined use of vemurafenib and cobimetinib, a selective inhibitor of MEK, yielded a significant improvement in PFS and response rate, compared to vemurafenib monotherapy, along with an advantage in OS, which did not cross the pre-specified significance bounderies (COBRIM trial). In treatment-naïve patients with mutated BRAF, both anti PD-1-based immunotherapy and BRAF-targeted agents are feasible therapeutic options, with the former and latter agents being associated with more durable and earlier responses, respectively. As suggested by National Comprehensive Cancer Network (NCCN) guidelines, the use of combined BRAF and MEK inhibitors in patients with progressive disease after immunotherapy, is also feasible, but it is not supported by category 1 evidence, in view of the lack of studies conducted in this setting. The main objective of this phase II trial is to evaluate the efficacy and safety of the combined use of vemurafenib plus cobimetinib in advanced melanoma patients who have received first-line systemic immunotherapy for inoperable locally advanced / metastatic disease.